As a consequence of significant advancements in immune checkpoint blocking, lung cancer patients' treatment paradigms have changed. The standard of care for patients with locally advanced/metastatic lung cancer without EGFR/ALK mutations or extensive-stage lung cancer is immune-checkpoint inhibitor (ICI) therapy, either as solo or combination therapy. The use of ICIs as neoadjuvant or adjuvant treatment in patients with early-stage lung cancer is also being studied in an increasing number of clinical studies. Both PD-L1 expression and the amount of tumor mutations have been investigated extensively for patient selection, although none of these indicators is optimal. Collaboration is required to create a multidimensional immunogram that incorporates complementing predictive biomarkers for customized immunotherapy because of the intricate connections between tumor cells, the tumor microenvironment, and host immunity that contribute to cancer. Additionally, controlling acquired resistance to ICI therapy remains a difficulty due to the widespread use of ICIs. A better understanding of the biological mechanisms behind acquired resistance to ICIs may assist overcome these obstacles.
The lack of a thorough understanding of the tumor immune microenvironment (TIME) and the interactions between tumor cells and stromal cells has hampered the development of new immunotherapies and patient stratification, despite the fact that numerous studies have indicated that ICI therapy holds promise as an important strategy to improve the prognosis of patients with lung cancer. Therefore, deeper comprehension of TIME is required to make it easier to identify prognostic and predictive biomarkers and provide fresh concepts for tailoring tumor immunotherapy approaches for lung cancer patients.
Immunotherapy is still a hot topic in the rapidly evolving field of cancer. This Research Topic seeks to offer a venue for the dissemination and discussion of new findings in the area of immunotherapy using immune checkpoint inhibitors in lung cancer. Original Research papers, Review articles, Systematic Reviews, and Mini-Reviews are all welcome. Interest-related subjects include, but are not limited to:
(1) New discoveries on the processes driving ICI resistance, such as hampered HLA Class I Antigen processing;
(2) New preclinical or clinical research on the use of ICIs in cancer therapy;
(3) To anticipate the therapeutic success of PD-1, additional biomarkers are being developed and validated; examples include the use of antigenicity, regulatory molecules on cancer cells, or cancer stem cells in the treatment of lung cancer;
(4) The alterations in the tumor microenvironment and their effects on how well patients respond to immunotherapy with ICIs (for example, the rise in tumor-infiltrating immune cells is sometimes referred to as having the ability to convert immunologically "cool" tumors into "hot" tumors).
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
As a consequence of significant advancements in immune checkpoint blocking, lung cancer patients' treatment paradigms have changed. The standard of care for patients with locally advanced/metastatic lung cancer without EGFR/ALK mutations or extensive-stage lung cancer is immune-checkpoint inhibitor (ICI) therapy, either as solo or combination therapy. The use of ICIs as neoadjuvant or adjuvant treatment in patients with early-stage lung cancer is also being studied in an increasing number of clinical studies. Both PD-L1 expression and the amount of tumor mutations have been investigated extensively for patient selection, although none of these indicators is optimal. Collaboration is required to create a multidimensional immunogram that incorporates complementing predictive biomarkers for customized immunotherapy because of the intricate connections between tumor cells, the tumor microenvironment, and host immunity that contribute to cancer. Additionally, controlling acquired resistance to ICI therapy remains a difficulty due to the widespread use of ICIs. A better understanding of the biological mechanisms behind acquired resistance to ICIs may assist overcome these obstacles.
The lack of a thorough understanding of the tumor immune microenvironment (TIME) and the interactions between tumor cells and stromal cells has hampered the development of new immunotherapies and patient stratification, despite the fact that numerous studies have indicated that ICI therapy holds promise as an important strategy to improve the prognosis of patients with lung cancer. Therefore, deeper comprehension of TIME is required to make it easier to identify prognostic and predictive biomarkers and provide fresh concepts for tailoring tumor immunotherapy approaches for lung cancer patients.
Immunotherapy is still a hot topic in the rapidly evolving field of cancer. This Research Topic seeks to offer a venue for the dissemination and discussion of new findings in the area of immunotherapy using immune checkpoint inhibitors in lung cancer. Original Research papers, Review articles, Systematic Reviews, and Mini-Reviews are all welcome. Interest-related subjects include, but are not limited to:
(1) New discoveries on the processes driving ICI resistance, such as hampered HLA Class I Antigen processing;
(2) New preclinical or clinical research on the use of ICIs in cancer therapy;
(3) To anticipate the therapeutic success of PD-1, additional biomarkers are being developed and validated; examples include the use of antigenicity, regulatory molecules on cancer cells, or cancer stem cells in the treatment of lung cancer;
(4) The alterations in the tumor microenvironment and their effects on how well patients respond to immunotherapy with ICIs (for example, the rise in tumor-infiltrating immune cells is sometimes referred to as having the ability to convert immunologically "cool" tumors into "hot" tumors).
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
